Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and purpose: Patients commonly take complementary medicines in conjunction with conventional drugs without clear evidence of safety or the risk of herb–drug interactions. The aim of this study was to assess potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between St John's wort and gliclazide in healthy subjects with different cytochrome P450 2C9 (CYP2C9) genotypes. Experimental approach: A crossover controlled study was conducted in 21 healthy subjects. Each received gliclazide (80 mg) either alone or during 15 days treatment with St John's wort. The area under the plasma concentration–time curve (AUC 0−∞), apparent clearance (CL/F) and elimination half‐life (t1/2) of gliclazide and incremental changes in glucose and insulin AUC 0−4 were compared.CYP2C9*2 and CYP2C9*3 alleles were identified using PCR followed by restriction enzyme digestion analysis. Key results: St John's wort significantly altered gliclazide pharmacokinetics in all except for four healthy subjects. The mean ratio and 90% confidence interval (CI) of gliclazide AUC 0−∞and CL/F were 0.67 (0.55–0.81) and 1.50 (1.24–1.81), respectively, after St John's wort treatment. St John's wort decreased gliclazide t1/2, with mean ratio and 90% CI of 0.85 (0.74–0.93). There were no significant changes in glucose or insulin AUC 0−4 after St John's wort treatment and no significant differences according to CYP2C9 genotype. Conclusions and implications: Treatment with St John's wort significantly increases the apparent clearance of gliclazide which is independent of CYP2C9 genotype. People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy. British Journal of Pharmacology(2008)153, 1579–1586; doi:10.1038/sj.bjp.0707685; published online 21 January 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davis, Daly, Walsh, Ilett, Beilby, Dusci, L. J., & Barrett, P. H. R. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00162.x · Cited by 75 · cited 2×
“Gliclazide is extensively metabolized in the liver (Davis et al., 2000) to at least eight identified metabolites (Oida et al.”
Background
Cited by
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
“In addition, 80 clinical trials were retrieved in 78 publications.([76-152]) One clinical trial was found to be published twice.”
Borrelli, F., & Izzo, A. A. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9146-8 · Cited by 288
Gurley, B., Fifer, E., & Gardner, Z. (2012) · Planta Medica · doi:10.1055/s-0031-1298331 · Cited by 165
Clinically and pharmacologically relevant interactions of antidiabetic drugs
May, M., & Schindler, C. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816638050 · Cited by 160
Metadata
- Authors
- Xu, H., Williams, K. M., Liauw, W. S., Murray, M., Day, R. O., & McLachlan, A. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 153
- Issue
- 7
- Pages
- 1579-1586
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1650615725
- Cited by
- 93
- References
- 1
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. https://app.cochat.ai/papers/10.1038/sj.bjp.0707685
- The paper
- Xu, H., Williams, K. M., Liauw, W. S., Murray, M., Day, R. O., & McLachlan, A. J. (2008). Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.